Key result
Prophylactic treatment with bisoprolol preserved left ventricular ejection fraction and attenuated doxorubicin-induced cardiotoxicity in rats.
Why the study?
Evidence is lacking for routine cardioprotective prophylaxis against doxorubicin cardiotoxicity in low-risk oncological patients, and the distinct roles of individual prophylactic medications required clarification.
Does prophylactic treatment with bisoprolol, perindopril, or eplerenone prevent doxorubicin-induced cardiotoxicity in a healthy rat model?
Does prophylactic treatment with bisoprolol, perindopril, or eplerenone prevent doxorubicin-induced cardiotoxicity in a healthy rat model?
Prophylactic bisoprolol or perindopril effectively mitigates doxorubicin-induced cardiotoxicity and improves survival in a healthy rat model.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for prophylactic bisoprolol in doxorubicin cardiotoxicity; human trials needed before clinical consideration.
BACKGROUND: Cardiomyopathy is a common side effect of doxorubicin (DOX) chemotherapy. Despite intensive research efforts in the field, there is still no evidence available for routine cardioprotective prophylaxis to prevent cardiotoxicity in the majority of oncological patients at low risk of cardiovascular disease. We have recently demonstrated the advantages of a prophylactic, combined heart failure therapy in an experimental model of DOX-induced cardiomyopathy. In the current work, we focus on individually applied prophylactic medications studied in the same translational environment to clarify their distinct roles in the prevention of DOX cardiotoxicity. METHODS: Twelve-week-old male Wistar rats were divided into 5 subgroups. Prophylactic β-blocker (BB, bisoprolol), angiotensin-converting enzyme inhibitor (ACEI, perindopril) or aldosterone antagonist (AA, eplerenone) treatments were applied 1 week before DOX administration, then 6 cycles of intravenous DOX chemotherapy were administered. Rats receiving only intravenous DOX or saline served as positive and negative controls. Blood pressure, heart rate, body weight, and echocardiographic parameters were monitored in vivo. Two months after the last DOX administration, the animals were sacrificed, and their heart and serum samples were frozen in liquid nitrogen for histological, mechanical, and biochemical measurements. RESULTS: All prophylactic treatments increased the survival of DOX-receiving animals. The lowest mortality rates were seen in the BB and ACEI groups. The left ventricular ejection fraction was only preserved in the BB group. The DOX-induced increase in the isovolumetric relaxation time could not be prevented by any prophylactic treatment. A decreased number of apoptotic nuclei and a preserved myocardial ultrastructure were found in all groups receiving prophylactic cardioprotection, while the DOX-induced fibrotic remodelling and the increase in caspase-3 levels could only be substantially prevented by the BB and ACEI treatments. CONCLUSION: Primary prophylaxis with cardioprotective agents like BB or ACEI has a key role in the prevention of DOX-induced cardiotoxicity in healthy rats. Future human studies are necessary to implement this finding in the clinical management of oncological patients free of cardiovascular risk factors.
No takes yet. Share an insight, caveat, or question.
Lódi et al. (2020) studied Doxorubicin-induced cardiomyopathy (n=45). Prophylactic bisoprolol, perindopril, or eplerenone vs. Doxorubicin only or saline was evaluated on Left ventricular ejection fraction at follow-up (p=0.0357). Prophylactic treatment with bisoprolol preserved left ventricular ejection fraction and attenuated doxorubicin-induced cardiotoxicity in rats.
Synapse has enriched 10 related papers. Consider them for comparative context: